A Phase 4 interventional study of Neffy and Adrenaline in Allergic Reactions, sponsored by ARS Pharmaceuticals, Inc.. Recruiting at 6 sites in United States. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by ARS Pharmaceuticals, Inc. · Phase 4, Interventional, and Treatment
Among 300 studies in Hypersensitivity with a site in United States — 32 open to participants now, 40 under way, 1 of them phase 3. Hypersensitivity · United States.
Among the 300 studies in Hypersensitivity with a site in United States, this one is the 18th largest by planned enrollment of the 220 interventional ones that give a count, is one of 11 that started in 2025, is one of 18 in phase 4, reaches primary completion later than 13 of the 38 other live ones, and was the 284th registered.
1,055 studies on the registry are indexed under Hypersensitivity; 149 are open to participants now.
Browse Hypersensitivity studies →32 of the 300 studies in Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 12+
Lumicell, Inc. · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–50
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12 mo–17 yrs
Qifeng Zhang · Sites in United States, China
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 100 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 51 (51%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
300 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 63 · Phase 3 41 · Phase 4 18
First in 1996; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 73 across 691 interventional studies indexed under Hypersensitivity.
Median enrollment 60 across the 220 interventional studies, 200 across the 76 observational. Of the 243 that completed or were terminated, 104 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
117 of 300 have an industry lead sponsor. The 10 most frequent:
ARS Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
ARS Pharmaceuticals, Inc. has 1 study filed under Hypersensitivity — fewer than ten, so there is no comparison to draw.
11 of the studies in Hypersensitivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT07447869National Institute of Allergy and Infectious Diseases (NIAID)LYmph Node eXamination in Cat Allergen Immunotherapy | 2027-01-27 |
| NCT03914664Vanderbilt University Medical CenterNeural Correlates of Sensory Phenomena in Tourette Syndrome | 2027-02-28 |
| NCT06834165ARS Pharmaceuticals, Inc.Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy | 2027-04 |
Add all 11 to your calendar (.ics) → With an account.
Among the 300 studies in Hypersensitivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Has any medical condition that precludes treatment with epinephrine as assessed by the Investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Neffy
Drug: Adrenaline
Epinephrine nasal spray
Epinephrine injection
AEs after epinephrine treatment within 2 hours
Time frame: 2 hours
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Apr 2027, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epinephrine
ARS Pharmaceuticals, Inc.